The Role of Obesity in Type 2 Diabetes Mellitus-An Overview

被引:125
作者
Chandrasekaran, Preethi [1 ]
Weiskirchen, Ralf [2 ]
机构
[1] UT Southwestern Med Ctr Dallas, 5323 Harry Hines Blvd ND10 504, Dallas, TX 75390 USA
[2] Univ Hosp Aachen, Rheinisch Westfalische TH RWTH, Inst Mol Pathobiochem Expt Gene Therapy & Clin Che, D-52074 Aachen, Germany
关键词
obesity; type; 2; diabetes; pathophysiology; incidence; prevalence; management; therapeutic approach; in vivo studies; clinical trials; IMPROVES INSULIN-RESISTANCE; ADIPOSE-TISSUE; OXIDATIVE STRESS; METABOLIC SYNDROME; WEIGHT MANAGEMENT; PEPTIDE-1; ANALOG; FAT ACCUMULATION; MOUSE MODEL; WHITE; OVERWEIGHT;
D O I
10.3390/ijms25031882
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Obesity or excessive weight gain is identified as the most important and significant risk factor in the development and progression of type 2 diabetes mellitus (DM) in all age groups. It has reached pandemic dimensions, making the treatment of obesity crucial in the prevention and management of type 2 DM worldwide. Multiple clinical studies have demonstrated that moderate and sustained weight loss can improve blood glucose levels, insulin action and reduce the need for diabetic medications. A combined approach of diet, exercise and lifestyle modifications can successfully reduce obesity and subsequently ameliorate the ill effects and deadly complications of DM. This approach also helps largely in the prevention, control and remission of DM. Obesity and DM are chronic diseases that are increasing globally, requiring new approaches to manage and prevent diabetes in obese individuals. Therefore, it is essential to understand the mechanistic link between the two and design a comprehensive approach to increase life expectancy and improve the quality of life in patients with type 2 DM and obesity. This literature review provides explicit information on the clinical definitions of obesity and type 2 DM, the incidence and prevalence of type 2 DM in obese individuals, the indispensable role of obesity in the pathophysiology of type 2 DM and their mechanistic link. It also discusses clinical studies and outlines the recent management approaches for the treatment of these associated conditions. Additionally, in vivo studies on obesity and type 2 DM are discussed here as they pave the way for more rigorous development of therapeutic approaches.
引用
收藏
页数:21
相关论文
共 127 条
[1]   Translational Significance of Heme Oxygenase in Obesity and Metabolic Syndrome [J].
Abraham, Nader G. ;
Junge, Joshua M. ;
Drummond, George S. .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2016, 37 (01) :17-36
[2]   The c-Jun NH2-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser307 [J].
Aguirre, V ;
Uchida, T ;
Yenush, L ;
Davis, R ;
White, MF .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (12) :9047-9054
[3]   ER stress in obesity pathogenesis and management [J].
Ajoolabady, Amir ;
Liu, Simin ;
Klionsky, Daniel J. ;
Lip, Gregory Y. H. ;
Tuomilehto, Jaakko ;
Kavalakatt, Sina ;
Pereira, David M. ;
Samali, Afshin ;
Ren, Jun .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2022, 43 (02) :97-109
[4]   Metabolic syndrome - a new world-wide definition. A consensus statement from the international diabetes federation [J].
Alberti, KGMM ;
Zimmet, P ;
Shaw, J .
DIABETIC MEDICINE, 2006, 23 (05) :469-480
[5]   Rasminogen activator inhibitor-1, adipose tissue and insulin resistance [J].
Alessi, Marie-Christine ;
Poggi, Marjorie ;
Juhan-Vague, Irene .
CURRENT OPINION IN LIPIDOLOGY, 2007, 18 (03) :240-245
[6]  
Amer Diabet Assoc, 2013, DIABETES CARE, V36, pS67, DOI [10.2337/dc11-S062, 10.2337/dc11-S011, 10.2337/dc12-s011, 10.2337/dc13-S011, 10.2337/dc10-S011, 10.2337/dc13-S067, 10.2337/dc10-S062, 10.2337/dc14-S081, 10.2337/dc12-s064]
[7]   2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2022 [J].
American Diabetes Association Professional Practice Committee .
DIABETES CARE, 2022, 45 :S17-S38
[8]  
[Anonymous], 2021, Diabetes Atlas Numbers
[9]   Body Weight Considerations in the Management of Type 2 Diabetes [J].
Apovian, Caroline M. ;
Okemah, Jennifer ;
O'Neil, Patrick M. .
ADVANCES IN THERAPY, 2019, 36 (01) :44-58
[10]   Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study [J].
Astrup, Arne ;
Rossner, Stephan ;
Van Gaal, Luc ;
Rissanen, Aila ;
Niskanen, Leo ;
Al Hakim, Mazin ;
Madsen, Jesper ;
Rasmussen, Mads F. ;
Lean, Michael E. J. .
LANCET, 2009, 374 (9701) :1606-1616